Cited by 973BRCA gene mutations in cancerWomen's cancer prevention and managementBreast Lesions and Carcinomas

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation

Open access

Meijers-Heijboer, Hanne, van Geel, Bert, van Putten, Wim L.J., Henzen-Logmans, Sonja C., Seynaeve, Caroline, Menke-Pluymers, Marian B.E., Bartels, Carina C.M., Verhoog, Leon C., van den Ouweland, Ans M.W., Niermeijer, Martinus F., Brekelmans, Cecile T.M., Klijn, Jan G.M.·2001·New England Journal of Medicine

DOI 10.1056/nejm200107193450301

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Women with a BRCA1 or BRCA2 mutation have a high risk of breast cancer and may choose to undergo prophylactic bilateral total mastectomy. We investigated the efficacy of this procedure in such women. METHODS: We conducted a prospective study of 139 women with a pathogenic BRCA1 or BRCA2 mutation who were enrolled in a breast-cancer surveillance program at the Rotterdam Family Cancer Clinic. At the time of enrollment, none of the women had a history of breast cancer. Seventy-six of these women eventually underwent prophylactic mastectomy, and the other 63 remained under regular surveillance. The effect of mastectomy on the incidence of breast cancer was analyzed by the Cox proportional-hazards method in which mastectomy was modeled as a time-dependent covariate. RESULTS: No cases of breast cancer were observed after prophylactic mastectomy after a mean (+/-SE) follow-up of 2.9+/-1.4 years, whereas eight breast cancers developed in women under regular surveillance after a mean follow-up of 3.0+/-1.5 years (P=0.003; hazard ratio, 0; 95 percent confidence interval, 0 to 0.36). The actuarial mean five-year incidence of breast cancer among all women in the surveillance group was 17+/-7 percent. On the basis of an exponential model, the yearly incidence of breast cancer in this group was 2.5 percent. The observed number of breast cancers in the surveillance group was consistent with the expected number (ratio of observed to expected cases, 1.2; 95 percent confidence interval, 0.4 to 3.7; P=0.80). CONCLUSIONS: In women with a BRCA1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm200107193450301

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,450
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing, J., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,399
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,428
Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: II. BRCA1 and BRCA2
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Lerman, C., Narod, S., Schulman, K., Hughes, C., Gomez-Caminero, A., Bonney, G., Gold, K., Trock, B., Main, D., Lynch, J., et al. (1996) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.275.24.1885 · Cited by 840
BRCA1 Testing in Families With Hereditary Breast-Ovarian Cancer
Lerman, C. E. (1996) · JAMA · doi:10.1001/jama.1996.03530480027036 · Cited by 826
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A. F., Snyder, C., Watson, P. A., Cannon‐Albright, L., Isaacs, C. J., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 670

Show all 33 references

Research works printed but not linked: 4

Whittemore AS, 1997, Am J Hum Genet, 60, 496
Hartmann LC, 2000, Proc Am Assoc Cancer Res, 41, 222
Kriege M, 2000, Eur J Cancer, 36, S137
Zion SM, 2000, Prog Proc Am Soc Clin Oncol, 19, 441a

Sorted by citations

Items 801–900 of 970

Genetic Factors in Breast Cancer
Ardern-Jones, A. T. (2010) · doi:10.1002/9781118784921.ch3
Moral approaches to genetic screening and testing
Mallia, P. (2004) · Radboud Repository (Radboud University)
MANAGEMENT CHOICES AND REPRODUCTIVE CONCERNS IN YOUNG WOMEN WITH BRCA MUTATIONS: A QUALITATIVE THEMATIC ANALYSIS
Schnipper, L. H. (2008) · D-Scholarship@Pitt (University of Pittsburgh)
Psychological impact of genetic testing for Lynch syndrome in new patients with colorectal cancer and educational-support groups for female BRCA-mutation carriers
Landsbergen, K. M. (2011) · Radboud Repository (Radboud University)
Hereditary Breast and Ovarian Cancers
Yang, W., Shi, D., & Liu, J. (2007) · doi:10.1142/9789812790811_00027
Modificadores de penetrância de mutações germinativas no gene TP53 em famílias brasileiras com diagnóstico clínico da síndrome de Li-Fraumeni e Li-Fraumeni like: impacto dos polimorfismos intragênicos do TP53 e de genes
Achatz, M. (2008) · doi:10.11606/t.5.2008.tde-29012009-172419
Treatment of Breast Cancer: New Approaches
Sheikh, N., Shehzadi, S., & Batool, A. (2012) · InTech eBooks · doi:10.5772/45765
“effective therapeutic approach for breast cancers with BRCA1 and BRCA2 mutations (Meijers-Heijboer et al., 2001).”
Background
Factors Associated with Early Versus Late Development of Breast and Ovarian Cancer in BRCA1 and BRCA2 Positive Women
Pickarski, J. (2010) · Digital Commons-TMC (Texas Medical Center)
BRCA1 and BRCA2 in Breast Cancer and Ovarian Cancer
Cassidy, M. R., & Mendez, J. E. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1423-4_6
“The available options are prophylactic bilateral, or risk-reducing, mastectomy in patients with no cancer diagnosis [ 52 – 55 ], therapeutic mastectomy with contralateral prophylactic mastectomy in those with a cancer diagnosis [ 5 , 56 ], and fi nally, prophylactic bilateral salpingooophorectomy (PBSO) performed alon…”
Background
Genetic Screening and Counseling for High-Risk Populations
Daly, M. (2006) · Springer eBooks · doi:10.1007/0-387-31056-8_25
Breast Cancer Screening in Women with a Familial or Genetic Predisposition: the role of MRI
Kriege, M. (2006) · RePub (Erasmus University Rotterdam)
Avaliação da patogenicidade de mutações germinativas de significado desconhecido nos genes BRCA1 e BRCA2 em famílias portuguesas.
Santos, C. G. R. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/g1ph-4s91
La chromastatine : peptide cryptique de la chromogranine a, regulateur autocrine de la secretion des catecholamines par les cellules chromaffines
Galindo, E. (1992)
Response to ethical dissections of the case
Lucassen, A. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545450.014
Risk Reduction Strategies: Surgical Perspective
Spiguel, L. R., & Hansen, N. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5891-3_8
The Impact of Prophylactic Salpingo-oophorectomy on Health in Women who carry a BRCA1 or BRCA2 Mutation
Finch, A. (2011) · TSpace (University of Toronto)
Bioethics and Medicolegal Aspects in Breast Cancer Reconstruction
Urban, C. D. A., Rabinovich, Í., Hurley, J., & Rietjens, M. (2013) · Springer eBooks · doi:10.1007/978-88-470-2652-0_49
“Although there are no randomized prospective trials that evaluated the efficacy of prophylactic bilateral mastectomy, and not many studies have considered this issue, the literature shows that bilateral prophylactic mastectomy reduces the risk of breast cancer by approximately 90 % in BRCA1/BRCA2 mutation carriers and…”
Background
Familial Breast Cancer, Prevention, Risk Factors and Genetics – Highlights from the San Antonio Breast Cancer Symposium (SABCS) Poster Presentations
Bauerschlag, D., Schem, C., Mundhenke, C., Meinhold-Heerlein, I. M., Jonat, W., & Maass, N. (2006) · Breast Care · doi:10.1159/000092604
Breast Cancer Risk Assessment and Risk Reduction
Mir, R., Singh, V. P., & Sodhi, P. (2008) · Apollo Medicine · doi:10.1016/s0976-0016(11)60477-8
Risk-Reducing Mastectomy: Who Is a Candidate and What Are the Outcomes?
Newman, L. A. (2013) · Current Breast Cancer Reports · doi:10.1007/s12609-013-0110-3
Genetische Beratung beim familiären Mammakarzinom
Pichert, G. (2008) · Therapeutische Umschau · doi:10.1024/0040-5930.65.4.235
“Verschiedene Studien [31, 32] haben gezeigt, dass die bilaterale prophylaktische Mastektomie das Risiko, an Brustkrebs zu erkranken um ≥ 90% senken kann.”
Background
A Patient With Metastatic Breast Cancer 15 Years After Bilateral Prophylactic Total Mastectomy and Oophorectomy
El-Amm, J., Ghanem, H., Zeck, J. C., Akin, E. A., & Siegel, R. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2012.05.002
One Case of BRCA2 Germline Mutation Ovarian Cancer Mother and Carrier Daughter found by Genetic Counseling
Lee, E. J., Jeong, H. J., & Kim, M. K. (2013) · Journal of genetic medicine · doi:10.5734/jgm.2013.10.2.124
Current and Evolving Therapeutic Options in the Treatment of Early Breast Cancer
Higa, G. M. (2011) · Clinical Medicine Reviews in Women s Health · doi:10.4137/cmrwh.s1636
Erfelijke vormen van mammacarcinoomerfelijk carcinoom
van Asperen, C. J., & de Bock, G. H. (2003) · Bijblijven · doi:10.1007/bf03059722
Surgical Management of Inherited Susceptibility to Breast Cancer
Freisinger, F., & Domchek, S. M. (2009) · Springer eBooks · doi:10.1007/978-0-387-87583-5_4
Considerations in genetic counseling for inherited breast cancer predisposition
Robson, M. E., & Offit, K. (2002) · Seminars in Radiation Oncology · doi:10.1053/srao.2002.35255
La chirurgie prophylactique du cancer du sein: réflexion critique
Bourstyn, E. (2006) · Psycho-Oncologie · doi:10.1007/s10332-006-0115-5
The Optimization of Breast Conservation
Dooley, W. C., Keshtgar, M., Tot, T., Yamamoto, D., & El-Tamer, M. B. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/456378
Hereditary Breast and Ovarian Cancer: Structures of Care in Austria
Kroiss, R., Bikas, D., Winkler, V., Muhr, D., Fürhauser, C., Tea, M., Fleischmann, E., Hereditary, A., Kubista, E., & Wagner, T. M. U. (2006) · Breast Care · doi:10.1159/000091401
Ovarian cancer: an update
Justus, K., & Anasti, J. N. (2003) · Current Surgery · doi:10.1016/s0149-7944(02)00733-x
The Breast Cancer Genes
Haque, M. A., Sarkar, S., & Mallick, A. (1970) · TAJ Journal of Teachers Association · doi:10.3329/taj.v17i2.3461
“In women with a BRCA1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up.(20)”
Background
Mutations in Families at High Risk for Breast Cancer
Cheung, P. (2006) · JAMA · doi:10.1001/jama.296.17.2091-a
Surgical Management of Hereditary Breast Cancer
Plasilova, M. L., & Chagpar, A. B. (2015) · Current Breast Cancer Reports · doi:10.1007/s12609-014-0169-5
Resonancia magnética y cáncer mamario contralateral
Serrano, A., Evangelio, B., & Benavent, A. L. (2008) · Progresos de Obstetricia y Ginecología · doi:10.1016/s0304-5013(08)71081-1
La mastectomía profiláctica evaluada desde una perspectiva ética
Nebril, B. A. (2004) · Cirugía Española · doi:10.1016/s0009-739x(04)78937-x
Principi della chirurgia oncoplastica e della ricostruzione mammaria immediata dopo mastectomia per carcinoma o mastectomia profilattica
Cothier-Savey, I., & Rimareix, F. (2012) · EMC - Tecniche Chirurgiche - Chirurgia Plastica¸ Ricostruttiva ed Estetica · doi:10.1016/s1769-6704(12)62599-6
Principios de la cirugía oncoplástica y de la reconstrucción mamaria inmediata tras mastectomía por carcinoma o mastectomía profiláctica
Cothier-Savey, I., & Rimareix, F. (2012) · EMC - Cirugía Plástica Reparadora y Estética · doi:10.1016/s1634-2143(12)62748-4
E18. Management of high-risk women; assessing the risk
Devilee, P. (2004) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(04)90599-x
Author Reply: Decision-Making Management of Women with a High Risk of Developing Breast and Ovarian Cancer
Heemskerk‐Gerritsen, B. A. M., Brekelmans, C. T. M., & Seynaeve, C. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9878-1
“Both our present study as well as the prospective study by Meijers-Heijboer et al. 1 showed no breast cancer occurrence after PM in unaffected high-risk women.”
Self-citation
Maligne Tumoren der Brust
Heckmann, A., Breuing, K. H., Vogt, P. M., & Gohritz, A. (2011) · Springer eBooks · doi:10.1007/978-3-540-37573-9_68
Breast cancer: The challenges facing surgeons in the next two decades
O’Higgins, N. J. (2005) · The Surgeon · doi:10.1016/s1479-666x(05)80042-3
Improving the risk assessment of inherited breast and ovarian cancer : clinical significance of BRCA1/2 variants and risk modifiers
Brandão, R. D. (2012) · Research Publications (Maastricht University) · doi:10.26481/dis.20121031rb
Consulta de riesgo oncológico. Selección de grupos de riesgo y resultados
Cusidó, M., Colomé, C., Rodríguez, I., & Fábregas, R. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2008.06.027
Fr�he maligne Progression des heredit�ren medull�ren Schilddr�senkarzinoms
Lustig, B., & Rudisch, S. (2004) · Der Onkologe · doi:10.1007/s00761-003-0619-6
“Beispiele dafür sind die familiäre adenomatöse Polyposis coli (FAP, APC-Mutation) [2], das Magenkarzinom (Mutation von E-Cadherin) [3] und das Mammakarzinom (BRCA1- und BRCA2Mutationen) [4].”
Background
Overview of Genetic Testing in Cancer
Peter, I., & Chin, K. M. (2006) · Personalized Medicine · doi:10.2217/17410541.3.3.325
“BRCA mutation carriers have shown a 90% reduction in the risk of breast cancer following prophylactic mastectomy [11,12], and a 85% reduction in the risk of ovarian cancer and a 25% reduction of breast cancer following prophylactic oophorectomy [13].”
Background
RISK REDUCING BEHAVIORS IN A COMMUNITY SAMPLE OF WOMEN WITH A FAMILY HISTORY OF BREAST CANCER
Somers, T. J. (2007) · D-Scholarship@Pitt (University of Pittsburgh)
BILATERAL PROPHYLACTIC MASTECTOMY AND IMMEDIATE BREAST RECONSTRUCTION WITH IMPLANTS
Gahm, J. (2009) · Figshare
BRCA1 gene expression in relation to prognostic parameters of breast cancer
Kamal, M., Shaaban, Y. H., Shehata, M., El-Kashif, A. T., Habib, E. E., Gabal, K. M. A., & El-Naggar, S. I. (2011) · Oncology Reviews · doi:10.1007/s12156-011-0078-z
“This finding emphasizes the fact that despite thorough examination of the mastectomy specimens, the presence of an occult breast cancer cannot be ruled out completely and indicates that a form of surveillance after mastectomy might be relevant [40].”
Background
Breast conserving surgery and radiation as a choice for patients with BRCA mutations
Pinto, C., Kotinsley, K., & Trombetta, M. (2012) · Journal of Solid Tumors · doi:10.5430/jst.v2n5p45 · Cited by 1
Carcinoma mamario infiltrante tras mastectomía subcutánea
Moreno, J., Díez, J., Albisu, M., Ruiz, B., López-Duque, J. C., Eizaguirre, B., Luján, S., & Rodríguez‐Escudero, F. J. (2005) · Progresos de Obstetricia y Ginecología · doi:10.1016/s0304-5013(05)72353-0
Intérêt de l'ovariectomie bilatérale prophylactique dans la prévention du cancer du sein
Lefranc, J., Fournet, S., Lauratet, B., & Bensaid, C. (2004) · DSpace (Centre National De La Recherche Scientifique)
Cáncer de mama y ovario heredofamiliar. Reflexiones basadas en la evidencia
Rubio, D., Sánchez, C., & Martín, I. (2003) · Progresos de Obstetricia y Ginecología · doi:10.1016/s0304-5013(03)75948-2
The Psychosocial Impact of Prophylactic Mastectomy and Salpingo-Oophorectomy
Bresser, P. J. C. (2009) · RePub (Erasmus University Rotterdam)
Disclosure of genetic information within families: a case report
Crawford, G., & Lucassen, A. (2008) · Clinical Ethics · doi:10.1258/ce.2007.007051
Prophylaktische mammachirurgische Versorgung von BRCA-Mutationsträgerinnen
Trutschel, E., Hoffmann, J., Froster, U., Hartmann, W., Peek, A., & Marx, M. (2013) · Journal für Ästhetische Chirurgie · doi:10.1007/s12631-013-0250-3
Attitude pratique devant une famille à haut risque de cancer du sein et/ou de l’ovaire : le point de vue de l’endocrinologue
Courtillot, C., & Touraine, P. A. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2007.12.001
Tamoxifen after breast cancer reduces the risk of cancer in the second breast in BRCA1 and BRCA2 carriers
O'Regan, R. M. (2001) · Evidence-based obstetrics and gynecology/Evidence-based obstetrics & gynecology · doi:10.1054/ebog.2001.0267
Reducción de riesgo de cáncer de mama: nuevos avances, nuevas preguntas
Sánchez, A. C. (2007) · Anales (Reial Acadèmia de Medicina de la Comunitat Valenciana)
COMMENTARY Bias in Intervention Studies That Enroll Patients From High-Risk Clinics
Wacholder, S. (2015)
Prise en charge par le chirurgien d’une élévation du risque de cancer du sein
Bonnier, P., Coscas, Y., Eisinger, F., Fourquet, A., Jacquemier, J. D., Lesur, A., Séror, J.-Y., Villet, R., & Pujol, P. (2008) · Springer eBooks · doi:10.1007/978-2-287-71478-8_9
The role of TArgeTed TherApy in CAnCer TreATmenT
Harchark, S., Москаленко, М., Bernardo, S. G., Sivendran, M., Saenger, Y. M., & Sivendran, S. (2012)
Hereditary breast and ovarian cancers: genetic testing and its clinical implications
Pradnya, K., Shilpa, V., Narendra, J. B. N. J. B., Sarin, R., & Mumbai, N. (2007)
COMMENTARY Potential for Bias in Studies on Efficacy of Prophylactic Surgery for BRCA1 and BRCA2 Mutation
Klaren, H. M., Veer, L. J. V., van Leeuwen, F. E., & Rookus, M. A. (2015)
EDITORIALS Prophylactic Mastectomy: Obstacles and Benefits
Lynch, H. T., Lynch, J. F., & Rubinstein, W. S. (2001)
Hereditäres Mamma- und Ovarialkarzinom: BRCA1, BRCA2 und BRCA3
Kiechle, M. B. (2011) · Springer eBooks · doi:10.1007/978-3-642-15012-8_26
À propos d'une série rétrospective de cancers du sein diagnostiqués auprès de patientes présentant une mutation constitutionnelle des gènes BRCA1 ou BRCA2: traitement et suivi à long terme
Artiguenave, M. (2015) · HAL
Ovarian Cancer Family Syndromes and Genetic Testing
Axilbund, J. E., Gross, A. L., & Visvanathan, K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4685-1.50008-1
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age Dorina M. van der KolkGeertruida H. de BockBeike K. Leegte • Michael SchaapveldMarian J. E. MouritsJakob de Vries • Annemieke H. van der HoutJan C. Oosterwijk
Tudy, P. S. (2010)
Strategien zur Prävention des Mammakarzinoms
Bauerschlag, D., & Ruckhäberle, E. (2014) · Humanmedizin kompakt · doi:10.1007/s40355-014-0033-x
El concepto de riesgo y su aplicación al ámbito pediátrico
Recuerdo, H. Y., & Guitián, J. P. (2001)
A Primer for Obstetricians/Gynecologists
Meaney‐Delman, D. M., & Bellcross, C. A. (2013)
Choice of Management of Southern Chinese BRCA Mutation
Kwong, A., Wong, C. H. N., Shea, C., Suen, D. T. K., & Choi, C. (2010)
Az örökletes emlőrák szűrésének, megelőzésének és kezelésének új nemzetközi irányvonalai – hazai vonatkozásokkal
Romics, L., Kocsis, J., Ormándi, K., & Molnar, B. A. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30473
Malignant disease of the breast
Thiruchelvam, P. T. R., Svensson, W. E., & Lynn, J. T. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3120-5.00047-3
Risk-Reducing Surgery for Breast Cancer Patients with BRCA Mutations
Kim, E., Kim, S., & Noh, D. (2016) · Springer eBooks · doi:10.1007/978-4-431-55552-0_1
Генотип-фенотипические корреляции у больных раком молочной железы с мутациями BRCA1 (4153delA, 185delAG, 5382insC)
Bit-Sava, M., & Imyanitov, N. (2014)
Current Approach to Breast Cancer Risk Reduction for Women with Hereditary Predispositions to Breast Cancer
Tran, G., Helm, M., & Litton, J. K. (2016) · Current Breast Cancer Reports · doi:10.1007/s12609-016-0220-9
Mujeres con alta probabilidad de padecer cáncer de mama. Luces, sombras y muchos puntos oscuros Women with high risk of breast cancer. More bright spots than shadows and many dark spots
Caruncho, M. V. (2016)
Anti-Metastatic and Anti-Tumor growth effects of carnosol on breast cancer
Samri, S. A., & Mohammed, H. A. (2016)
Susceptibility genes in hereditary breast cancer
Vahteristo, P. (2003) · Työväentutkimus Vuosikirja
Prophylactic Mastectomy: still a controversial procedure?
Vaz, F. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Identification et prise en charge des femmes ayant des antécédents familiaux de cancer du sein
Heisey, R., & Carroll, J. C. (2016) · Canadian Family Physician
Hochrisikopatientin mit BRCA-1-Mutation – Risikofaktor Restdrüsengewebe nach prophylaktischer Mastektomie
Téoule, J., Harcos, A., Sohn, C., Heil, J., & Schott, S. (2017) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/s-0042-119611
“J Clin Oncol 2004; 22: 1055–1062 [10] Meijers-Heijboer H, van Geel B, van Putten WL et al.”
Background
Hochrisikopatientin mit BRCA-1-Mutation – Risikofaktor Restdrüsengewebe nach prophylaktischer Mastektomie
Téoule, J., Harcos, A., Sohn, C., Heil, J., & Schott, S. (2017) · TumorDiagnostik & Therapie · doi:10.1055/s-0043-103164
“[10] Meijers-Heijboer H, van Geel B, van Putten WL et al.”
Background
Bilateral Prophylactic Mastectomy and Immediate Breast Reconstruction in High-Risk Women: The Importance of Health-Related Quality of Life in Decision Making
Lemaine, V. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-5916-1
Risk-Reducing Surgery for BRCA1/2 Genetic Mutation Carriers
O’Donoghue, C., Orcutt, S. T., Pal, T., & Laronga, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-59198-8_4
LOS GENES BRCA1 y BRCA2. ESTUDIO MOLECULAR
Alonso, N., Iglesias, R. G., Rodríguez, L. M., Pargas, J. A. M., Blanco, I., San‐Miguel, A., & Gil, F. J. M. (2006) · Revista electrónica de biomedicina
Surgical Management of Breast Cancer in BRCA Mutation Carriers
Cronin, P. A., & Cody, H. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-59198-8_7
Breast Cancer Genetics
de Gouvêa, A. C. R. C., & Garber, J. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_8
The Cochrane Database of Systematic Reviews
Lostumbo, L., Carbine, N. E., & Wallace, J. (2004)
Surgical Oncology Overview
Sicard, M. A., & Li, B. D. �. (2017) · Wiley eBooks · doi:10.1002/9781119468868.ch16
Prognostic indicators of primary breast cancer in relation to patient's risk profile.
Bult, P. (2009) · Radboud Repository (Radboud University)
Diagnostic génétique du cancer du sein et de l’ovaire héréditaire: Clinical and molecular diagnosis of inherited breast-ovarian cancer
Chompret, A. (2003) · Imagerie de la Femme · doi:10.1016/s1776-9817(05)80643-1 · Cited by 4
Living at-Risk for Hereditary Breast Cancer: The Experiences of at-Risk Unaffected Women Who Live in Families Where a BRCA Gene Mutation Could Not be Found
Schroeder, A. D. (2016) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3v40k46q
Hereditary Breast Cancer in Selected Populations: Screening RECQL Gene in Ontario, Canada, and Exploring BRCA1/2 and PALB2 in the Caribbean
Ahmed, H. (2018) · TSpace (University of Toronto)
Overcoming Resistance to PARP Inhibition
Nowsheen, S., & Xia, F. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_6
A Pedigree of Familial Breast Cancer with Seven Breast Cancer Patients in Four Generations
Nakamura, I., NAGATSUKA, M., Matsuzaki, M., Katagata, N., Kiko, Y., & Nomizu, T. (2019) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.80.848
Implementation of Hereditary Gynecologic Cancer Clinic Utilizing Existing All Screening and Genetic Methods in Community-Based Hospital by Surgeon
Kim, M. K. (2019) · Gynecology & Reproductive Health · doi:10.33425/2639-9342.1083
Phyllodes Tumour and Selected Benign Breast Lesions
Shousha, S. (2020) · In clinical practice · doi:10.1007/978-3-030-42386-5_8

Authors: Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., Brekelmans, C. T. M., & Klijn, J. G. M.
Affiliations: Erasmus MC (NL)
ORCID: Meijers-Heijboer, Hanne
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-07-19
Volume: 345
Issue: 3
Pages: 159-164
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm200107193450301
OpenAlex: W2046809735
Cited by: 973
References: 33
Citations by year: 2026: 15 · 2025: 14 · 2024: 14 · 2023: 18 · 2022: 18 · 2021: 24 · 2020: 23 · 2019: 30 · 2018: 21 · 2017: 37 · 2016: 42 · 2015: 28 · 2014: 34 · 2013: 29 · 2012: 42
FWCI: 35.85
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, other-oa)
RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
Pure Amsterdam UMC (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Keywords: breast cancer, bilateral prophylactic mastectomy, BRCA1 mutation, BRCA2 mutation, hereditary breast cancer, breast cancer incidence, breast cancer surveillance, genetic susceptibility to cancer
MeSH terms: Adult, Breast Neoplasms, Female, Humans, Middle Aged, Mutation, Neoplasm Proteins, Prospective Studies, Transcription Factors, Mastectomy, Simple, Proportional Hazards Models, Genes, BRCA1, BRCA2 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks